Analysis of Clinical Characteristics and Prognosis of AML Patients with Co-Mutation of CEBPA Gene and GATA2 Gene
10.19746/j.cnki.issn1009-2137.2024.05.002
- VernacularTitle:急性髓系白血病CEBPA及GATA2基因共存突变患者的临床特征和预后分析
- Author:
Xue-Wei YANG
1
;
Shan-Shan LI
;
Yan-Hua SU
;
Jia-Yue SUN
;
Yu-Juan GAO
Author Information
1. 哈尔滨医科大学附属第一医院血液内科,黑龙江哈尔滨 150000
- Keywords:
acute myeloid leukemia;
CEBPA gene mutation;
GATA2 gene mutation;
coexisting gene mutation
- From:
Journal of Experimental Hematology
2024;32(5):1313-1316
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics and prognosis of patients with co-mutation of CEBPA gene and GATA2 gene,so as to facilitate clinicians to formulate more accurate individualized treatment plans for patients.Methods:A total of 43 acute myeloid leukemia(AML)patients with CEBPA double mutations and CEBPA-bZIP domain mutation admitted to the First Affiliated Hospital of Harbin Medical University from January 2017 to April 2022 were included,and the clinical characteristics and prognosis of patients with GA TA2 gene mutation among them were compared and analyzed.Results:The median age of patients with GA TA2 gene mutation was 48.0 years,which was significantly lower than 57.0 years of patients without GATA2 gene mutation(P＜0.05).However,there were no significant differences in sex,white blood cell count,hemoglobin concentration,platelet count,immunophenotype,bone marrow and peripheral blood blast cell ratio and complete remission rate between the two groups(P＞0.05).The median overall survival and event-free survival time of patients with GATA2 gene mutation were not reached,while those of patients without GATA2 gene mutation were 14.8 and 8.1 months,respectively(both P＜0.05).Conclusion:The median age of patients with GATA2 gene mutation is lower than that of patients without GATA2 gene mutation.GATA2 gene mutation further prolongs the survival time of AML patients with CEBPA double mutations and CEBPA-bZIP domain mutation.
